Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Reviews in Endocrine and Metabolic Disorders
Published in: Reviews in Endocrine and Metabolic Disorders 3/2021

Open Access 01-09-2021 | Valproate

Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer

Authors: M.J. Klomp, S.U. Dalm, M. de Jong, R.A. Feelders, J. Hofland, L.J. Hofland

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 3/2021

Login to get access

Abstract

Both somatostatin (SST) and somatostatin receptors (SSTRs) are proteins with important functions in both physiological tissue and in tumors, particularly in neuroendocrine tumors (NETs). NETs are frequently characterized by high SSTRs expression levels. SST analogues (SSAs) that bind and activate SSTR have anti-proliferative and anti-secretory activity, thereby reducing both the growth as well as the hormonal symptoms of NETs. Moreover, the high expression levels of SSTR type-2 (SSTR2) in NETs is a powerful target for therapy with radiolabeled SSAs. Due to the important role of both SST and SSTRs, it is of great importance to elucidate the mechanisms involved in regulating their expression in NETs, as well as in other types of tumors. The field of epigenetics recently gained interest in NET research, highlighting the importance of this process in regulating the expression of gene and protein expression. In this review we will discuss the role of the epigenetic machinery in controlling the expression of both SSTRs and the neuropeptide SST. Particular attention will be given to the epigenetic regulation of these proteins in NETs, whereas the involvement of the epigenetic machinery in other types of cancer will be discussed as well. In addition, we will discuss the possibility to target enzymes involved in the epigenetic machinery to modify the expression of the SST-system, thereby possibly improving therapeutic options.
Literature
1.
Olias G, Viollet C, Kusserow H, Epelbaum J, Meyerhof W. Regulation and function of somatostatin receptors. J Neurochem. 2004;89:1057–91.PubMedCrossRef
2.
3.
4.
Günther T, Tulipano G, Dournaud P, Bousquet C, Csaba Z, Kreienkamp H-J, et al. International Union of Basic and Clinical Pharmacology. CV. Somatostatin receptors: structure, function, ligands, and new nomenclature. Pharmacol Rev. 2018;70:763–835.PubMedPubMedCentralCrossRef
5.
Gatto F, Barbieri F, Arvigo M, Thellung S, Amaru J, Albertelli M, et al. Biological and biochemical basis of the differential efficacy of first and second generation Somatostatin receptor ligands in neuroendocrine neoplasms. Int J Mol Sci. 2019;20:3940.PubMedCentralCrossRef
6.
Barbieri F, Bajetto A, Pattarozzi A, Gatti M, Würth R, Thellung S, et al. Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept. 2013;2013:926295.PubMedPubMedCentralCrossRef
7.
Qian ZR, Li T, Ter-Minassian M, Yang J, Chan JA, Brais LK, et al. Association between Somatostatin receptor expression and clinical outcomes in neuroendocrine tumors. Pancreas. 2016;45:1386–93.PubMedPubMedCentralCrossRef
8.
Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, et al. Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch. 2002;440:461–75.PubMedCrossRef
9.
Evans AA, Crook T, Laws SA, Gough AC, Royle GT, Primrose JN. Analysis of somatostatin receptor subtype mRNA expression in human breast cancer. Br J Cancer. 1997;75:798–803.PubMedPubMedCentralCrossRef
10.
Qiu C-Z, Wang C, Huang Z-X, Zhu S-Z, Wu Y-Y, Qiu J-L. Relationship between somatostatin receptor subtype expression and clinicopathology, Ki-67, Bcl-2 and p53 in colorectal cancer. World J Gastroenterol. 2006;12:2011–5.PubMedPubMedCentralCrossRef
11.
Hennigs JK, Müller J, Adam M, Spin JM, Riedel E, Graefen M, et al. Loss of somatostatin receptor subtype 2 in prostate cancer is linked to an aggressive cancer phenotype, high tumor cell proliferation and predicts early metastatic and biochemical relapse. PLoS One. 2014;9:e100469.PubMedPubMedCentralCrossRef
12.
Werner C, Dirsch O, Dahmen U, Grimm M-O, Schulz S, Lupp A. Evaluation of Somatostatin and CXCR4 Receptor Expression in a Large Set of Prostate Cancer Samples Using Tissue Microarrays and Well-Characterized Monoclonal Antibodies. Transl Oncol. 2020;13:100801.PubMedPubMedCentralCrossRef
13.
Stafford ND, Condon LT, Rogers MJ, MacDonald AW, Atkin SL. The expression of somatostatin receptors 1 and 2 in benign, pre-malignant and malignant laryngeal lesions. Clin Otolaryngol Allied Sci. 2003;28:314–9.PubMedCrossRef
14.
Zou Y, Tan H, Zhao Y, Zhou Y, Cao L. Expression and selective activation of somatostatin receptor subtypes induces cell cycle arrest in cancer cells. Oncol Lett. 2019;17:1723–31.PubMed
15.
Singh S, Granberg D, Wolin E, Warner R, Sissons M, Kolarova T, et al. Patient-reported burden of a neuroendocrine tumor (NET) diagnosis: results from the first global survey of patients with NETs. J Glob Oncol. 2016;3:43–53.PubMedPubMedCentralCrossRef
16.
Zandee WT, de Herder WW. The evolution of neuroendocrine tumor treatment reflected by ENETS guidelines. Neuroendocrinology. 2018;106:357–65.PubMedCrossRef
17.
Hofland J, Kaltsas G, de Herder WW. Advances in the diagnosis and Management of Well-Differentiated Neuroendocrine Neoplasms. Endocr Rev. 2020;41:371–403.PubMedCentralCrossRef
18.
Mizutani G, Nakanishi Y, Watanabe N, Honma T, Obana Y, Seki T, et al. Expression of Somatostatin receptor (SSTR) subtypes (SSTR-1, 2A, 3, 4 and 5) in neuroendocrine tumors using real-time RT-PCR method and immunohistochemistry. Acta Histochem Cytochem. 2012;45:167–76.PubMedPubMedCentralCrossRef
19.
Stueven AK, Kayser A, Wetz C, Amthauer H, Wree A, Tacke F, et al. Somatostatin analogues in the treatment of neuroendocrine tumors: past. Present and Future Int J Mol Sci. 2019;20:3049.CrossRef
20.
Bergsma H, van Vliet EI, Teunissen JJ, Kam BL, de Herder WW, Peeters RP, et al. Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. Best Pract Res Clin Gastroenterol. 2012;26:867–81.PubMedCrossRef
21.
Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol. 2007;46:723–34.PubMedCrossRef
22.
Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, et al. Patient-reported outcomes with lanreotide autogel/depot for carcinoid syndrome: an international observational study. Dig Liver Dis. 2016;48:552–8.PubMedCrossRef
23.
O'Toole D, Ducreux M, Bommelaer G, Wemeau JL, Bouche O, Catus F, et al. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance. Cancer. 2000;88:770–6.PubMedCrossRef
24.
Appetecchia M, Baldelli R. Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine tumours, current aspects and new perspectives. J Exp Clin Cancer Res. 2010;29:19.PubMedPubMedCentralCrossRef
25.
Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;27:4656–63.PubMedCrossRef
26.
Caplin ME, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.PubMedCrossRef
27.
Brabander T, van der Zwan WA, Teunissen JJM, Kam BLR, Feelders RA, de Herder WW, et al. Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0,Tyr3]octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors. Clin Cancer Res. 2017;23:4617–24.PubMedCrossRef
28.
Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival. J Clin Oncol. 2008;26:2124–30.PubMedCrossRef
29.
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for Midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.PubMedPubMedCentralCrossRef
30.
van Vliet EI, van Eijck CH, de Krijger RR, Nieveen van Dijkum EJ, Teunissen JJ, Kam BL, et al. Neoadjuvant Treatment of Nonfunctioning Pancreatic Neuroendocrine Tumors with [177Lu-DOTA0,Tyr3]Octreotate. J Nucl Med. 2015;56:1647–53.PubMedCrossRef
31.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. J Clin Oncol. 2005;23:2754–62.PubMedCrossRef
32.
Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol. 2010;21:548–55.PubMedCrossRef
33.
Diakatou E, Kaltsas G, Tzivras M, Kanakis G, Papaliodi E, Kontogeorgos G. Somatostatin and dopamine receptor profile of gastroenteropancreatic neuroendocrine tumors: an immunohistochemical study. Endocr Pathol. 2011;22:24–30.PubMedCrossRef
34.
Di Domenico A, Wiedmer T, Marinoni I, Perren A. Genetic and epigenetic drivers of neuroendocrine tumours (NET). Endocr Relat Cancer. 2017;24:R315–R34.PubMedCrossRef
35.
36.
37.
38.
39.
Jeffries MA, Sawalha AH. Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve? Expert Rev Clin Immunol. 2015;11:45–58.PubMedPubMedCentralCrossRef
40.
Finnerty BM, Gray KD, Moore MD, Zarnegar R, Fahey Iii TJ. Epigenetics of gastroenteropancreatic neuroendocrine tumors: a clinicopathologic perspective. World J Gastrointest Oncol. 2017;9:341–53.PubMedPubMedCentralCrossRef
41.
42.
Maleszewska M, Kaminska B. Is glioblastoma an epigenetic malignancy? Cancers (Basel). 2013;5:1120–39.CrossRef
43.
Alaskhar Alhamwe B, Khalaila R, Wolf J, von Bülow V, Harb H, Alhamdan F, et al. Histone modifications and their role in epigenetics of atopy and allergic diseases. Allergy Asthma Clin Immunol. 2018;14:39.PubMedPubMedCentralCrossRef
44.
Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23–38.PubMedCrossRef
45.
Hervouet E, Peixoto P, Delage-Mourroux R, Boyer-Guittaut M, Cartron P-F. Specific or not specific recruitment of DNMTs for DNA methylation, an epigenetic dilemma. Clin Epigenetics. 2018;10:17.PubMedPubMedCentralCrossRef
46.
Hessmann E, Johnsen S, Siveke J, Ellenrieder V. Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon? Gut. 2016;66:168–79.PubMedCrossRef
47.
48.
Klieser E, Urbas R, Stattner S, Primavesi F, Jager T, Dinnewitzer A, et al. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome. Hum Pathol. 2017;65:41–52.PubMedCrossRef
49.
Alvarez MJ, Subramaniam PS, Tang LH, Grunn A, Aburi M, Rieckhof G, et al. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors. Nat Genet. 2018;50:979–89.PubMedPubMedCentralCrossRef
50.
51.
Petersenn S, Rasch AC, Presch S, Beil FU, Schulte HM. Genomic structure and transcriptional regulation of the human somatostatin receptor type 2. Mol Cell Endocrinol. 1999;157:75–85.PubMedCrossRef
52.
Xu Y, Berelowitz M, Bruno JF. Characterization of the promoter region of the human somatostatin receptor subtype 2 gene and localization of sequences required for estrogen-responsiveness. Mol Cell Endocrinol. 1998;139:71–7.PubMedCrossRef
53.
Pscherer A, Dorflinger U, Kirfel J, Gawlas K, Ruschoff J, Buettner R, et al. The helix-loop-helix transcription factor SEF-2 regulates the activity of a novel initiator element in the promoter of the human somatostatin receptor II gene. EMBO J. 1996;15:6680–90.PubMedPubMedCentralCrossRef
54.
Torrisani J, Hanoun N, Laurell H, Lopez F, Maoret JJ, Souque A, et al. Identification of an upstream promoter of the human somatostatin receptor, hSSTR2, which is controlled by epigenetic modifications. Endocrinology. 2008;149:3137–47.PubMedCrossRef
55.
Veenstra MJ, van Koetsveld PM, Dogan F, Farrell WE, Feelders RA, Lamberts SWJ, et al. Epidrug-induced upregulation of functional somatostatin type 2 receptors in human pancreatic neuroendocrine tumor cells. Oncotarget. 2018;9:14791–802.PubMedCrossRef
56.
Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F, et al. Pharmacological inhibition of class IIA HDACs by LMK-235 in pancreatic neuroendocrine tumor cells. Int J Mol Sci. 2018;19:3128.PubMedCentralCrossRef
57.
Taelman VF, Radojewski P, Marincek N, Ben-Shlomo A, Grotzky A, Olariu CI, et al. Upregulation of key molecules for targeted imaging and therapy. J Nucl Med. 2016;57:1805–10.PubMedCrossRef
58.
Jin XF, Auernhammer CJ, Ilhan H, Lindner S, Nölting S, Maurer J, et al. Combination of 5-fluorouracil with epigenetic modifiers induces radiosensitization, somatostatin receptor 2 expression, and radioligand binding in neuroendocrine tumor cells in vitro. J Nucl Med. 2019;60:1240–6.PubMedCrossRef
59.
Guenter R, Aweda T, Carmona Matos DM, Jang S, Whitt J, Cheng Y-Q, et al. Overexpression of somatostatin receptor type 2 in neuroendocrine tumors for improved Ga68-DOTATATE imaging and treatment. Surgery. 2019;167:189–96.PubMedCrossRef
60.
Sun L, Qian Q, Sun G, Mackey LV, Fuselier JA, Coy DH, et al. Valproic acid induces NET cell growth arrest and enhances tumor suppression of the receptor-targeted peptide-drug conjugate via activating somatostatin receptor type II. J Drug Target. 2016;24:169–77.PubMedCrossRef
61.
Arvidsson Y, Johanson V, Pfragner R, Wangberg B, Nilsson O. Cytotoxic effects of Valproic acid on neuroendocrine tumour cells. Neuroendocrinology. 2016;103:578–91.PubMedCrossRef
62.
Li SC, Martijn C, Cui T, Essaghir A, Luque RM, Demoulin JB, et al. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells. PLoS One. 2012;7:e48411.PubMedPubMedCentralCrossRef
63.
Hofving T, Arvidsson Y, Almobarak B, Inge L, Pfragner R, Persson M, et al. The neuroendocrine phenotype, genomic profile and therapeutic sensitivity of GEPNET cell lines. Endocr Relat Cancer. 2018;25:367–80.PubMedPubMedCentralCrossRef
64.
Alvarez MJ, Yan P, Alpaugh ML, Bowden M, Sicinska E, Zhou CW, et al. Reply to ‘H-STS, L-STS and KRJ-I are not authentic GEPNET cell lines’. Nat Genet. 2019;51:1427–8.PubMedPubMedCentralCrossRef
65.
Guenter RE, Aweda T, Carmona Matos DM, Whitt J, Chang AW, Cheng EY, et al. Pulmonary Carcinoid Surface Receptor Modulation Using Histone Deacetylase Inhibitors. Cancers (Basel). 2019;11:767.CrossRef
66.
Chen G, Jaskula-Sztul R, Harrison A, Dammalapati A, Xu W, Cheng Y, et al. KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-a for targeted neuroendocrine cancer therapy. Biomaterials. 2016;97:22–33.PubMedPubMedCentralCrossRef
67.
Jaskula-Sztul R, Chen G, Dammalapati A, Harrison A, Tang W, Gong S, et al. AB3-loaded and tumor-targeted Unimolecular micelles for medullary thyroid Cancer treatment. J Mater Chem B. 2017;5:151–9.PubMedCrossRef
68.
Jaskula-Sztul R, Xu W, Chen G, Harrison A, Dammalapati A, Nair R, et al. Thailandepsin A-loaded and octreotide-functionalized unimolecular micelles for targeted neuroendocrine cancer therapy. Biomaterials. 2016;91:1–10.PubMedPubMedCentralCrossRef
69.
Liu J, Li H, Sun L, Wang Z, Xing C, Yuan Y. Aberrantly methylated-differentially expressed genes and pathways in colorectal cancer. Cancer Cell Int. 2017;17:75.PubMedPubMedCentralCrossRef
70.
Misawa K, Misawa Y, Kondo H, Mochizuki D, Imai A, Fukushima H, et al. Aberrant methylation inactivates somatostatin and somatostatin receptor type 1 in head and neck squamous cell carcinoma. PLoS One. 2015;10:e0118588.PubMedPubMedCentralCrossRef
71.
Shen Z, Chen X, Li Q, Zhou C, Li J, Ye H, et al. SSTR2 promoter hypermethylation is associated with the risk and progression of laryngeal squamous cell carcinoma in males. Diagn Pathol. 2016;11:10.PubMedPubMedCentralCrossRef
72.
Zhao J, Liang Q, Cheung KF, Kang W, Lung RWM, Tong JHM, et al. Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells. Cancer. 2013;119:304–12.PubMedCrossRef
73.
Shi X, Li X, Chen L, Wang C. Analysis of somatostatin receptors and somatostatin promoter methylation in human gastric cancer. Oncol Lett. 2013;6:1794–8.PubMedPubMedCentralCrossRef
74.
Kim HJ, Kang TW, Haam K, Kim M, Kim SK, Kim SY, et al. Whole genome MBD-seq and RRBS analyses reveal that hypermethylation of gastrointestinal hormone receptors is associated with gastric carcinogenesis. Exp Mol Med. 2018;50:1–14.PubMedPubMedCentral
75.
Sun G, Mackey LV, Coy DH, Yu CY, Sun L. The histone deacetylase inhibitor vaproic acid induces cell growth arrest in hepatocellular carcinoma cells via suppressing notch signaling. J Cancer. 2015;6:996–1004.PubMedPubMedCentralCrossRef
76.
Sun L, He Q, Tsai C, Lei J, Chen J, Makcey LV, et al. HDAC inhibitors suppressed small cell lung cancer cell growth and enhanced the suppressive effects of receptor-targeting cytotoxins via upregulating somatostatin receptor II. Am J Transl Res. 2018;10:545–53.PubMedPubMedCentral
77.
Franko-Tobin LG, Mackey LV, Huang W, Song X, Jin B, Luo J, et al. Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics. Oncologist. 2012;17:220–32.PubMedPubMedCentralCrossRef
78.
Tsai C, Leslie JS, Franko-Tobin LG, Prasnal MC, Yang T, Vienna Mackey L, et al. Valproic acid suppresses cervical cancer tumor progression possibly via activating Notch1 signaling and enhances receptor-targeted cancer chemotherapeutic via activating somatostatin receptor type II. Arch Gynecol Obstet. 2013;288:393–400.PubMedCrossRef
79.
Gailhouste L, Liew LC, Hatada I, Nakagama H, Ochiya T. Epigenetic reprogramming using 5-azacytidine promotes an anti-cancer response in pancreatic adenocarcinoma cells. Cell Death Dis. 2018;9:468.PubMedPubMedCentralCrossRef
80.
Wang B, Zhao L, Chi W, Cao H, Cui W, Meng W. Aberrant methylation-mediated downregulation of lncRNA SSTR5-AS1 promotes progression and metastasis of laryngeal squamous cell carcinoma. Epigenetics Chromatin. 2019;12:35.PubMedPubMedCentralCrossRef
81.
Liu Z, Marquez M, Nilsson S, Holmberg AR. Incubation with somatostatin, 5-aza decitabine and trichostatin up-regulates somatostatin receptor expression in prostate cancer cells. Oncol Rep. 2008;20:151–4.PubMed
82.
White-Al Habeeb NMA, Ho LT, Olkhov-Mitsel E, Kron K, Pethe V, Lehman M, et al. Integrated analysis of epigenomic and genomic changes by DNA methylation dependent mechanisms provides potential novel biomarkers for prostate cancer. Oncotarget. 2014;5:7858–69.PubMedPubMedCentralCrossRef
83.
Zhao J, Liang Q, Cheung KF, Kang W, Dong Y, Lung RWM, et al. Somatostatin receptor 1, a novel EBV-associated CpG hypermethylated gene, contributes to the pathogenesis of EBV-associated gastric cancer. Br J Cancer. 2013;108:2557–64.PubMedPubMedCentralCrossRef
84.
Chen W, Ding R, Tang J, Li H, Chen C, Zhang Y, et al. Knocking out SST gene of BGC823 gastric Cancer cell by CRISPR/Cas9 enhances migration, invasion and expression of SEMA5A and KLF2. Cancer Manag Res. 2020;12:1313–21.PubMedPubMedCentralCrossRef
85.
Pyronnet S, Bousquet C, Najib S, Azar R, Laklai H, Susini C. Antitumor effects of somatostatin. Mol Cell Endocrinol. 2008;286:230–7.PubMedCrossRef
86.
Wu J, Gu Y, Xiao Y, Xia C, Li H, Kang Y, et al. Characterization of DNA methylation associated gene regulatory networks during stomach Cancer progression. Front Genet. 2018;9:711.PubMedCrossRef
87.
Jackson K, Soutto M, Peng D, Hu T, Marshal D, El-Rifai W. Epigenetic silencing of somatostatin in gastric cancer. Dig Dis Sci. 2011;56:125–30.PubMedCrossRef
88.
Li H, Liu JW, Liu S, Yuan Y, Sun LP. Bioinformatics-based identification of methylated-differentially expressed genes and related pathways in gastric Cancer. Dig Dis Sci. 2017;62:3029–39.PubMedCrossRef
89.
Zhang X, Yang JJ, Kim YS, Kim KY, Ahn WS, Yang S. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Int J Oncol. 2010;36:405–14.PubMed
90.
Ricketts CJ, Morris MR, Gentle D, Brown M, Wake N, Woodward ER, et al. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics. 2012;7:278–90.PubMedPubMedCentralCrossRef
91.
Morris MR, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, et al. Functional epigenomics approach to identify methylated candidate tumour suppressor genes in renal cell carcinoma. Br J Cancer. 2008;98:496–501.PubMedPubMedCentralCrossRef
92.
Patai ÁV, Valcz G, Hollósi P, Kalmár A, Péterfia B, Patai Á, et al. Comprehensive DNA methylation analysis reveals a common ten-gene methylation signature in colorectal adenomas and carcinomas. PLoS One. 2015;10:e0133836.PubMedPubMedCentralCrossRef
93.
Leiszter K, Sipos F, Galamb O, Krenács T, Veres G, Wichmann B, et al. Promoter hypermethylation-related reduced somatostatin production promotes uncontrolled cell proliferation in colorectal cancer. PLoS One. 2015;10:e0118332.PubMedPubMedCentralCrossRef
94.
Patai ÁV, Barták BK, Péterfia B, Micsik T, Horváth R, Sumánszki C, et al. Comprehensive DNA methylation and mutation analyses reveal a methylation signature in colorectal sessile serrated adenomas. Pathol Oncol Res. 2017;23:589–94.PubMedCrossRef
95.
Kok-Sin T, Mokhtar NM, Ali Hassan NZ, Sagap I, Mohamed Rose I, Harun R, et al. Identification of diagnostic markers in colorectal cancer via integrative epigenomics and genomics data. Oncol Rep. 2015;34:22–32.PubMedPubMedCentralCrossRef
96.
Mori Y, Cai K, Cheng Y, Wang S, Paun B, Hamilton JP, et al. A genome-wide search identifies epigenetic silencing of Somatostatin, Tachykinin-1, and 5 other genes in Colon Cancer. Gastroenterology. 2006;131:797–808.PubMedCrossRef
97.
Zhang M, Lv X, Jiang Y, Li G, Qiao Q. Identification of aberrantly methylated differentially expressed genes in glioblastoma multiforme and their association with patient survival. Exp Ther Med. 2019;18:2140–52.PubMedPubMedCentral
98.
Ongenaert M, Wisman GB, Volders HH, Koning AJ, Zee AG, van Criekinge W, et al. Discovery of DNA methylation markers in cervical cancer using relaxation ranking. BMC Med Genet. 2008;1:57.
99.
van der Zee RP, Richel O, van Noesel CJM, Novianti PW, Ciocanea-Teodorescu I, van Splunter AP, et al. Host cell deoxyribonucleic acid methylation markers for the detection of high-grade anal intraepithelial Neoplasia and anal Cancer. Clin Infect Dis. 2019;68:1110–7.PubMedCrossRef
100.
Jin Z, Mori Y, Hamilton JP, Olaru A, Sato F, Yang J, et al. Hypermethylation of the somatostatin promoter is a common, early event in human esophageal carcinogenesis. Cancer. 2008;112:43–9.PubMedCrossRef
101.
Zhang Z, Tang H, Wang Z, Zhang B, Liu W, Lu H, et al. MiR-185 targets the DNA methyltransferases 1 and regulates global DNA methylation in human glioma. Mol Cancer. 2011;10:124.PubMedPubMedCentralCrossRef
102.
Misawa K, Mima M, Imai A, Mochizuki D, Misawa Y, Endo S, et al. The neuropeptide genes SST, TAC1, HCRT, NPY, and GAL are powerful epigenetic biomarkers in head and neck cancer: a site-specific analysis. Clin Epigenetics. 2018;10:52.PubMedPubMedCentralCrossRef
103.
Misawa K, Mochizuki D, Imai A, Endo S, Mima M, Misawa Y, et al. Prognostic value of aberrant promoter hypermethylation of tumor-related genes in early-stage head and neck cancer. Oncotarget. 2016;7:26087–98.PubMedPubMedCentralCrossRef
104.
Marek L, Hamacher A, Hansen FK, Kuna K, Gohlke H, Kassack MU, et al. Histone deacetylase (HDAC) inhibitors with a novel connecting unit linker region reveal a selectivity profile for HDAC4 and HDAC5 with improved activity against chemoresistant cancer cells. J Med Chem. 2013;56:427–36.PubMedCrossRef
105.
Jang S, Yu XM, Odorico S, Clark M, Jaskula-Sztul R, Schienebeck CM, et al. Novel analogs targeting histone deacetylase suppress aggressive thyroid cancer cell growth and induce re-differentiation. Cancer Gene Ther. 2015;22:410–6.PubMedCrossRef
106.
Wang C, Henkes LM, Doughty LB, He M, Wang D, Meyer-Almes FJ, et al. Thailandepsins: bacterial products with potent histone deacetylase inhibitory activities and broad-spectrum antiproliferative activities. J Nat Prod. 2011;74:2031–8.PubMedPubMedCentralCrossRef
Metadata
Title
Epigenetic regulation of somatostatin and somatostatin receptors in neuroendocrine tumors and other types of cancer
Authors
M.J. Klomp
S.U. Dalm
M. de Jong
R.A. Feelders
J. Hofland
L.J. Hofland
Publication date
01-09-2021
Publisher
Springer US
Published in
Reviews in Endocrine and Metabolic Disorders / Issue 3/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI
https://doi.org/10.1007/s11154-020-09607-z

Other articles of this Issue 3/2021

Reviews in Endocrine and Metabolic Disorders 3/2021 Go to the issue

ReviewPaper

Imaging of neuroendocrine tumors: A pictorial review of the clinical value of different imaging modalities

REVIEW PAPER

Foreword to the special issue on advances in neuroendocrine neoplasms

ReviewPaper

Chemotherapy in NEN: still has a role?

ReviewPaper

Theranostics in neuroendocrine tumors: an overview of current approaches and future challenges

ReviewPaper

"Present and future of immunotherapy in Neuroendocrine Tumors"

ReviewPaper

Evaluating cost-effectiveness in the management of neuroendocrine neoplasms

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits